8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A detailed regulatory guide to alprostadil compounding under FDA sections 503A and 503B, covering Caverject and MUSE approval history, trimix legality, outsourcing facility rules, and state-level pharmacy requirements.
A clinical deep-dive into alprostadil (Caverject, MUSE) FAERS adverse event reports, FDA labeling history, post-market surveillance findings, and what they mean for prescribers and patients.
A complete regulatory timeline for alprostadil (Caverject and MUSE), covering original NDA approvals, label updates, post-market safety data, and current prescribing guidance.
A complete guide to alprostadil's regulatory history across the US, EU, and beyond, covering FDA approval dates, prescribing label requirements, post-market safety data, and what clinicians need to know before prescribing Caverject or MUSE.
A comprehensive review of FDA label changes for alprostadil (Caverject, MUSE, Edex) from 2020 through 2026, covering safety revisions, post-market surveillance data, and clinical guidance for prescribers.
A physician-reviewed deep-dive into the FDA approval history, patent disputes, label updates, and post-market safety obligations for alprostadil (Caverject and MUSE), including what compounding pharmacy rules mean for patients today.
A clinical review of alprostadil's FDA history, current label, post-market safety data, and next-generation delivery systems in development for erectile dysfunction.
A detailed comparison of how the FDA and EMA regulate alprostadil (Caverject, MUSE, Vitaros), including approval timelines, labeled indications, safety monitoring, and post-market requirements.